Martin Fan
Stock Analyst at Wedbush
(2.88)
# 1,949
Out of 4,931 analysts
7
Total ratings
71.43%
Success rate
20.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Fan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANAB AnaptysBio | Maintains: Outperform | $40 → $45 | $19.57 | +129.94% | 2 | Aug 7, 2025 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $38 | $10.50 | +261.90% | 1 | Jul 9, 2025 | |
| ACRS Aclaris Therapeutics | Initiates: Outperform | $8 | $1.58 | +406.33% | 1 | May 28, 2025 | |
| ORKA Oruka Therapeutics | Reiterates: Outperform | $40 | $13.86 | +188.66% | 1 | May 15, 2025 | |
| ARTV Artiva Biotherapeutics | Reiterates: Outperform | $18 | $2.85 | +531.58% | 1 | Mar 25, 2025 | |
| ZBIO Zenas BioPharma | Initiates: Outperform | $35 | $14.37 | +143.56% | 1 | Mar 20, 2025 |
AnaptysBio
Aug 7, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $19.57
Upside: +129.94%
Cartesian Therapeutics
Jul 9, 2025
Initiates: Outperform
Price Target: $38
Current: $10.50
Upside: +261.90%
Aclaris Therapeutics
May 28, 2025
Initiates: Outperform
Price Target: $8
Current: $1.58
Upside: +406.33%
Oruka Therapeutics
May 15, 2025
Reiterates: Outperform
Price Target: $40
Current: $13.86
Upside: +188.66%
Artiva Biotherapeutics
Mar 25, 2025
Reiterates: Outperform
Price Target: $18
Current: $2.85
Upside: +531.58%
Zenas BioPharma
Mar 20, 2025
Initiates: Outperform
Price Target: $35
Current: $14.37
Upside: +143.56%